LUNGevity Foundation shared a post on LinkedIn:
“FDA approval alert!
On July 2, 2025 the US FDA granted accelerated approval to sunvozertinib for locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.
This offers a new therapeutic option for patients whose disease has progressed on or after chemotherapy treatment. Learn more here.”